Cardiac Overexpression of S100A6 Attenuates Cardiomyocyte Apoptosis and Reduces Infarct Size After Myocardial Ischemia-Reperfusion

Azadeh Mofid, MD, PhD; Nadav S. Newman, BA, BSc; Paul J. H. Lee, MSC; Cynthia Abbasi, MSc; Pratiek N. Matkar, MSc; Dmitriy Rudenko, BSc; Michael A. Kuliszewski, BSc; Hao H. Chen, MSc; Kolsoom Afrasiabi, MD; James N. Tzoporis, PhD; Anthony O. Gramolini, PhD; Kim A. Connelly, MBBS, PhD; Thomas G. Parker, MD, PhD; Howard Leong-Poi, MD

Background—Cardiomyocyte-specific transgenic mice overexpressing S100A6, a member of the family of EF-hand calcium-binding proteins, develop less cardiac hypertrophy, interstitial fibrosis, and myocyte apoptosis after permanent coronary ligation, findings that support S100A6 as a potential therapeutic target after acute myocardial infarction. Our purpose was to investigate S100A6 gene therapy for acute myocardial ischemia-reperfusion.

Methods and Results—We first performed in vitro studies to examine the effects of S100A6 overexpression and knockdown in rat neonatal cardiomyocytes. S100A6 overexpression improved calcium transients and protected against apoptosis induced by hypoxia-reoxygenation via enhanced calcineurin activity, whereas knockdown of S100A6 had detrimental effects. For in vivo studies, human S100A6 plasmid or empty plasmid was delivered to the left ventricular myocardium by ultrasound-targeted microbubble destruction in Fischer-344 rats 2 days prior to a 30-minute ligation of the left anterior descending coronary artery followed by reperfusion. Control animals received no therapy. Pretreatment with S100A6 gene therapy yielded a survival advantage compared to empty-plasmid and nontreated controls. S100A6-pretreated animals had reduced infarct size and improved left ventricular systolic function, with less myocyte apoptosis, attenuated cardiac hypertrophy, and less cardiac fibrosis.

Conclusions—S100A6 overexpression by ultrasound-targeted microbubble destruction helps ameliorate myocardial ischemia-reperfusion, resulting in lower mortality and improved left ventricular systolic function post—ischemia-reperfusion via attenuation of apoptosis, reduction in cardiac hypertrophy, and reduced infarct size. Our results indicate that S100A6 is a potential therapeutic target for acute myocardial infarction. (J Am Heart Assoc. 2017;6:e004738. DOI: 10.1161/JAHA.116.004738.)

Key Words: apoptosis • gene therapy • hypertrophy • ischemia-reperfusion • S100A6 • ultrasound-targeted microbubble destruction

Early reperfusion by thrombolytic therapy or percutaneous coronary intervention limits infarct size and reduces mortality in patients presenting with acute ST-segment elevation myocardial infarction.1,2 Although outcomes have improved, morbidity and mortality still remain significant, with in-hospital mortality rates of 3% to 4%,3 30-day mortality rates of 5% to 7%,4 3-year rates of major adverse cardiovascular events ranging from 16% to 17%,5 and 30-day rehospitalization rates of 15% to 20%.6 Although essential, the acute restoration of blood flow within the epicardial coronary artery can lead to metabolic and structural events that result in a further loss of cardiomyocytes through multiple mechanisms, termed myocardial ischemia-reperfusion (I/R) injury.7,8 As a consequence, the development of new therapies to further reduce infarct size and preserve left ventricular (LV) systolic function after acute ST-segment elevation myocardial infarction remains a priority.9,11 Myocardial I/R injury is a complex, multifaceted process that has been extensively studied, with important contributing factors from oxidative stress, calcium overload, immune responses, inflammation, and impaired metabolism, leading to myocyte and endothelial cell loss by several mechanisms including apoptosis, necrosis, and autophagy.7,9 Thus, the ability to specifically target multiple underlying biologic
S100A6 Therapy for Acute Myocardial Infarction  Mofid et al

processes involved in reperfusion injury would be a key aspect in the development of novel therapeutic strategies to address myocardial I/R.

S100A6 is a member of a superfamily of EF-hand Ca\(^{2+}\)-binding proteins that regulate a wide array of cellular and molecular functions, including cell proliferation, differentiation, and survival as well as Ca\(^{2+}\) dynamics, cardiomyocyte contractility, hypertrophy, and apoptosis. S100A6 expression is increased in the heart after MI and inhibits the induction of the cardiac fetal gene promoters in cultured neonatal rat cardiac myocytes in vitro, which suggests that it plays a role in modulating cardiac hypertrophy. Overexpression of S100A6 in vitro prevented cardiomyocyte apoptosis induced by tumor necrosis factor-\(\alpha\) by interfering with p53 phosphorylation. Most recently, cardiac myocyte-specific transgenic mice overexpressing S100A6 showed attenuation of cardiac hypertrophy, less interstitial fibrosis, and reduced myocyte apoptosis compared to control animals in a permanent coronary ligation model of MI.

Given that S100A6 has the potential to modulate several key pathways involved in I/R injury, including myocyte apoptosis and Ca\(^{2+}\) dynamics, as well as positively influence cardiac hypertrophy, a key element in the remodeling process post-MI, we hypothesized that gene transfer of S100A6 would ameliorate myocardial reperfusion injury and attenuate LV systolic dysfunction in a rat model of I/R. The present study demonstrates that the mechanisms of S100A6 therapy in the setting of myocardial I/R are multifactorial, with effects on cardiomyocytes to reduce apoptosis, attenuate hypertrophy, and increase Ca\(^{2+}\) cycling. These findings, coupled with the positive data from transgenic mice, support S100A6 as a novel therapeutic target for acute myocardial I/R.

Methods

Neonatal Rat Cardiomyocyte Isolation and Purification

Rat neonatal ventricular myocytes (NRVM) from 2- to 3-day-old Fisher 344 rats (Charles River Laboratories International, Wilmington, MA) were isolated using a Worthington Neonatal Cardiomyocyte Isolation system (Worthington Biochemical Corporation, Lakewood, NJ; catalog #LK003303), according to the manufacturer’s protocol. In brief, 2- to 3-day-old rat pups were sacrificed by decapitation. After sterilization, the beating hearts were surgically removed and immediately placed in centrifuge tubes containing 30 to 40 mL of sterile calcium-magnesium–free Hanks Balanced Salt Solution (CMF HBSS, pH 7.4, Reagent 1) to chill and rinse. The tissue was minced with small scissors to less than 1 mm\(^3\) pieces while being kept at 0°C and then incubated overnight (16-20 hours) at 2°C to 8°C in 10 mL of CMF HBSS containing purified trypsin (Reagent 2) at a final concentration of 50 \(\mu g/mL\).

After the incubation time, tissue and buffer were mixed with trypsin inhibitor (Reagent 3) and oxygenated for 30 seconds by passing oxygen over the surface of the liquid. Tissue and buffer were warmed to 30°C to 37°C in a water bath, and collagenase (Reagent 4) was added, followed by incubation for 30 to 45 minutes at 37°C on a slowly rotating or shaking instrument. The tubes were removed from the incubator, cells released by triturating 10 times using standard 10 mL plastic serological pipettes, and then filtered through the cell strainer into a fresh 50-mL centrifuge tube. Cells were sedimented at 180g for 5 minutes, and the final cell pellet was suspended in Dulbecco Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) (Life Technologies, Carlsbad, CA; catalog #11320-033) for 24 hours after seeding), were inoculated with Ad-CMV-Null (2.8 \(\times\) 10\(^9\) PFU/mL, MOI:100), Ad-CMV-emGFP-hS100A6 (2.8 \(\times\) 10\(^9\) PFU/mL, MOI:100), and Ad-GFP-U6-shS100A6-shRNA (4.0 \(\times\) 10\(^9\) PFU/mL, MOI:100) adenoviral vectors in 250 \(\mu L/cm^2\) of serum containing 7% Horse serum plus 7% fetal bovine serum DMEM/F12 growth medium (Life Technologies, catalog #11330-032) for 24 hours. All adenoviral vectors were constructed in Vector BioLabs (Malvern, PA).

shRNA sequence (TRCN0000087874): CCGG-GCTTTGAGTTCACTAATGAAGCT-TCTACAATGAAGCT-CTCGAG-AGCTTCATTGTAGATCAAAGC-TT
Hairpin sequence: GCTTTGATCTACAATGAAGCT

In Vitro Transduction and Adenoviral Vectors

Cultured neonatal rat cardiomyocytes (5 \(\times\) 10\(^4\)/cm\(^2\) cells grown for 48 hours after seeding), were inoculated with Ad-CMV-Null (2.25 \(\times\) 10\(^{10}\) PFU/mL, MOI:100), Ad-CMV-emGFP-hS100A6 (2.8 \(\times\) 10\(^9\) PFU/mL, MOI:100), and Ad-GFP-U6-shS100A6-shRNA (4.0 \(\times\) 10\(^9\) PFU/mL, MOI:100) adenoviral vectors in CMF HBSS containing 7% Horse serum plus 7% fetal bovine serum DMEM/F12 growth medium (Life Technologies, catalog #11330-032) for 24 hours. All adenoviral vectors were constructed in Vector BioLabs (Malvern, PA).

shRNA sequence (TRCN0000087874): CCGG-GCTTTGAGTTCACTAATGAAGCT-TCTACAATGAAGCT-CTCGAG-AGCTTCATTGTAGATCAAAGC-TT
Hairpin sequence: GCTTTGATCTACAATGAAGCT

The virus-containing growth medium was replaced with fresh medium after 24 hours, but cells were incubated for another 24 hours to have maximal expression of overexpressed gene (human S100A6) and downregulation of knocked-down gene (rat S100A6) at the time of hypoxia/reoxygenation (H/R) induction or calcium transient studies.
Real-Time Quantitative Polymerase Chain Reaction

Total RNA was extracted using Trizol reagent, and reverse-transcribed into cDNA using a reverse transcription system. Polymerase chain reaction (PCR) amplification was performed with Power SYBR Green PCR Master Mix in a StepOne. Gene expression levels were normalized with housekeeping gene rat TBP, and data were analyzed with StepOne software (Applied Biosystems, Foster City, CA) v2.1. The primers’ sequences we used were as follows (Table).

Protein Extraction and Western Blotting

Tissue samples were homogenized and protein concentrations determined according to the method of Bradford protein assay. The proteins of equal loading were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane. Membranes were incubated with rabbit monoclonal anti-S100A6 antibody (Novus Biologicals, Littleton, CO; catalog #NBP1-95284) or rabbit polyclonal anti–green fluorescent protein (GFP) antibody (Abcam, Cambridge, UK; catalog #ab6556) and anti-rabbit IgG horseradish peroxidase–conjugated (Promega, Madison, WI; catalog #W401B). Blots of proteins were probed with rabbit polyclonal anti-GAPDH primary antibody (Santa Cruz Biotechnologies, Dallas, TX; catalog #sc-25778) for internal reference. Secondary antibodies were detected using Immobilon Western chemiluminescence horseradish peroxidase substrate (Millipore, Billerica, MA; catalog #WBKLS0050). Band intensity was quantified by scanning densitometry using a VersaDoc Imaging System (Bio-Rad, Hercules, CA).

Hypoxia/Reoxygenation Induction In Vitro

Hypoxic conditions were created by incubating culture dishes in an airtight Plexiglas chamber with an atmosphere of 1% O2, 20% CO2, and 79% N2 at 37°C for 24 hours. Serum-free low-glucose growth medium, Dulbecco Modified Eagle Medium, DMEM × 1 (Life Technologies, Carlsbad, CA; catalog #11885-084) was preequilibrated in the hypoxic chamber overnight before use. Reperfusion/reoxygenation was simulated by returning the cultured cells to the incubator with an atmosphere of 95% air and 5% CO2 at 37°C for 6 hours in serum containing DMEM/F12 medium.

Intracellular Calcium Transients During Spontaneous Action Potential

Neonatal cardiomyocytes were incubated in 0.5 μmol/L Fura-2AM in serum-free medium (DMEM/F12 medium+50 units penicillin/50 μg) for 1 hour and washed with serum-free medium. A fluorescence microscope (Olympus IX81, Tokyo, Japan; X-cite 120Q. light source from EXFO, Quebec, QC, Canada; Fura 2B filterset from Semrock, Rochester, NY; using single-band excitation [387 nm] and single-band emission [510 nm], image acquisition with a Rolera MG plus EM-CCD from Q-Imaging, Surrey, BC, Canada; via Metamorph v7.6.3. software, Nashville, TN) was used to acquire calcium transients.17

Immunocytochemistry and TUNEL Apoptotic Detection Assay

Neonatal cardiomyocytes were grown directly onto glass slides and transduced with adenoviral vectors for overexpression or knockdown of S100A6. H/R injury was created by incubating in the hypoxic incubation chamber followed by reoxygenation, as described above. Cells were washed twice with 1× phosphate-buffered saline and fixed in 2%
paraformaldehyde. Tissue sections were permeabilized in either 2:1 ratio solution of ethanol:acetic acid (for terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL] slides) or 0.025% Triton X-100 for immunohistochemistry. Mouse monoclonal anti–cardiac trophin T antibody (Abcam, Cambridge, UK; catalog #ab10214), rabbit monoclonal anti–S100A6 antibody (Novus biologicals, Littleton, CO; catalog #NB1-95284), goat anti–mouse IgG (Cy5) (Abcam, catalog #ab6563-100), and donkey antirabbit IgG (FITC) (GeneTex Inc, Irvine, CA; catalog #GTX26798) were used for immunostaining.

Neonatal cardiac myocytes cultured overnight were treated with vehicle (phosphate-buffered saline) (endogenous level) or with pure recombinant S100A6 protein tagged to His (Life Technologies, Carlsbad, CA) at a concentration of 100 nmol/L each for 1 hour. Cells were then fixed with 4% paraformaldehyde, permeabilized, and incubated with sheep anti-S100A6 (1:400, R&D) and rabbit anti-Histidase fusion protein (1:800, Abcam) followed by fluorochrome-conjugated secondary antibodies, donkey anti–sheep Alexa 488 (1:400) or chicken anti–rabbit Alexa 543 (1:400) (Molecular Probes, Eugene, OR), respectively. Extracellular protein uptake and subcellular localization were visualized by confocal microscopy. Images were generated with a Zeiss (Oberkochen, Germany) LSM 700 confocal laser scanning microscope using excitation wavelength of 488 nm and 543 nm for Alexa green and red dyes, respectively.

A subset of sections was also processed for apoptotic cell labeling using Apoptag Red in situ Apoptosis Detection kit (Millipore, Billerica, MA; catalog #Z5605). The nuclei were counterstained with DAPI containing Vectashield mounting medium (Vector BioLabs, Malvern, PA; catalog #H1200).

Caspase 3/7 Activity Assay
Caspase 3/7 activity was measured using Caspase 3/7-Glo Assay (Promega, Madison, WI; catalog #G8091) by measuring the luminescence corresponding to the amount of caspase 3/7 activity from the total protein isolate. The luminescence was measured and quantified by a luminometer.

Calcineurin Phosphatase Activity Assay
A colorimetric assay kit was used to measure cellular CaN (PP2B) phosphatase activity (Enzo Life Science, Farmingdale, NY; catalog #BML-AK816-0001) in cellular extracts. Human recombinant CaN was included as a positive control.

Plasmid Preparation
An expression vector driven by a cytomegalovirus promoter was constructed for transfection of human S100A6-N-emGFP, in which the human S100A6 sequence was fused with emGFP at the N-terminus to create a fusion protein. GUS-N-eGFP was used as the empty plasmid for the control group. The plasmid vector was acquired through SIDNET (Toronto, ON, Canada) and was sequence-verified prior to use in vivo.

Ultrasound-Targeted Microbubble Destruction Gene Delivery
The study protocol was approved by the Animal Care and Use Committee at the Keenan Research Centre for Biomedical Science, St Michael’s Hospital, University of Toronto, in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Cationic lipid microbubbles (1×10⁹) were charge-coupled to 500 μg of plasmid DNA (S100A6 or empty plasmid), as previously described. Under anesthesia, a cannula was placed in the rat’s jugular vein for intravenous injections. For ultrasound-targeted microbubble destruction (UTMD), high-power ultrasound at a pulsing interval of 10 cardiac cycles at end-systole was transmitted to the LV via an S12 transducer (Sonos 5500, Philips Healthcare, Andover, MA) at a frequency of 5 MHz, 2 cm depth, power 120 V during intravenous infusion of plasmid-cationic microbubble complexes via the jugular vein over 5 minutes (Model AS50-Baxter). The probe was positioned to cut the LV in a transverse plane (short-axis) at the midpapillary level, and the transducer was slowly moved from the base to the apex to allow maximal myocardial delivery. Ultrasonic transmission was continued for an additional 25 minutes after plasmid-microbubble infusion to ensure maximal delivery of remaining circulating DNA-microbubble complexes. Animals were subsequently given Anafen 5 mg/kg and placed on a warming pad at 37°C and allowed to recover.

Ischemia/Reperfusion Induction Surgery
Ischemia/reperfusion injury was induced via left anterior descending (LAD) coronary artery ligation for 30 minutes followed by reperfusion in Fischer-344 rats, at day 2 after UTMD (S100A6 or empty plasmid). Control animals did not receive UTMD prior to I/R. Animals were anesthetized with inhaled 2% to 5% isoflurane in 1.5 L/min oxygen, intubated, and volume-controlled ventilated (110/min with tidal volume of 0.25 mL) with 1.5% isoflurane in 1.5 L/min oxygen using a rodent respirator (model 683, Harvard Apparatus, Holliston, MA). The toe-pinch method was used to ensure the adequacy of anesthetic. Buprenorphine (0.02 mg/kg subcutaneously [SC]) and Anafen (5 mg/kg SC) were administered prior to the surgery. After preparation of the surgical site with alcohol and povidone-iodine, under sterile conditions, the rat’s chest was opened. An incision was made in the skin on the left side of the chest, and the pectoral muscles were gently retracted to...
expose the ribs. An incision was made through the fourth intercostal space, and the ribs were gently spread to expose the heart.

A curved needle was passed through the myocardium beneath the LAD coronary artery just below the atrial appendage. Ischemia was induced by ligation of LAD with a 6-0 prolene ligature. The suture was then routed into a clamping device, which would compress the artery to induce a reversible occlusion. The procedure was successful when myocardium changed color from a red hue to pale and white. After 30 minutes the clamp was released, and the ligature was removed. Reperfusion was confirmed by observing the change from cyanotic to pink in the myocardium. The chest was compressed to expel intrapleural air. The ribs, muscle, and skin were sutured, saline was administered (10 mL/kg SC), and the animals were ventilated using room air until spontaneous breathing resumed. After recovery they were extubated and placed on a warming blanket. Successful I/R induction was confirmed by echocardiography after surgery. Animals were followed out to day 28, with a subgroup sacrificed at day 1 post-I/R. Euthanasia was performed by means of cervical dislocation while under isoflurane-induced anesthesia. On sacrifice, tissue was harvested for postmortem analyses.

Risk Area Assessment by Evans Blue
Under anesthesia, a cannula was placed in the jugular vein for intravenous (IV) injections. LAD ligation was performed as described above. At 15 minutes after ligation, a 2% solution (4 mL) of Evans blue (Sigma, St. Louis, MO) was injected over 1 minute through the IV catheter. Five minutes after injection animals were sacrificed, the heart was removed, and 1-mm-thick transverse sections of the LV were cut distal to the ligation site. Sections were fixed in 10% buffered formalin for 48 hours and imaged (Olympus E1 Camera system, Tokyo, Japan). Images were processed in Image J, and risk area was quantified (nonperfused area/total LV area). Evans blue marked the perfused region during ligation, and the risk area was delineated by the non–Evans blue–stained myocardium.

Two-Dimensional Echocardiography
Under anesthesia (inhaled isoflurane anaesthetic, 0.2 L/min medical air, 3% isoflurane via nose cone), echocardiography was performed using Vevo® 2100 system (Visual Sonics, Toronto, ON, Canada) with an MS250 transducer (13-24 MHz) before surgery and 1, 2, 3, 7, 14, and 28 days after I/R injury. A parasternal long-axis view was recorded, ensuring that the mitral and aortic valves and the apex were visualized. A short-axis view was recorded at the level of the midpapillary muscles. Both 2-dimensional and motion-mode views were recorded at the same level. LV end-diastolic dimension, end-systolic dimension, fractional shortening, fractional area change, and the circumferential extent of the akinetic segment of the LV were measured from the short-axis view. LV ejection fraction was measured in parasternal long-axis view using a monoplane Simpson technique. All values were averaged over 3 consecutive cycles.

Cardiomyocyte Size and Myocyte Hypertrophy
The extent of cardiac myocyte hypertrophy was determined from hematoxylin-eosin–stained sections. In brief, spindle-shaped cardiac myocytes with elliptical nuclei in a noninfarct region of transverse myocardial section were selected. The area of each cell was measured at the level of the nucleus using imaging software (NIS-Elements; Nikon, Tokyo, Japan), and the values were averaged. Approximately 3 cells per field at ×40 magnification were found with 2 fields randomly selected per sample slide. Each treatment group included 10 animals and 10 slides. The average diameter of 50 to 60 myocytes was then calculated for 10 animals in each treatment group.

Triphenyl-Tetrazolium Chloride and Masson Trichrome Stain
We used 2,3,5-triphenyl-tetrazolium chloride (TTC) staining (Sigma-Aldrich, St. Louis, MO; catalog #T8877-10G) to define the nonviable/infarcted myocardium in LV myocardial slices at 24 hours post-I/R. We also used Masson Trichrome Stain Kit (Polysciences Inc, Warminster, PA; catalog #25088-100) to detect collagen fibers (stained blue) and necrotic tissue in the infarcted area of the LV myocardium (stained pink).

TUNEL Apoptosis Assay
Analysis of apoptosis was performed in 1 LV section per animal, obtained from the region that showed maximal infarct size. Using the ApopTag® Peroxidase In Situ Apoptosis Detection Kit (EMD Millipore, Darmstadt, Germany), apoptotic cardiomyocytes were detected through labeling and detecting DNA strand breaks by TUNEL (Millipore, Billerica, MA; catalog #S7160). The apoptotic index (FITC+ nuclei×100/DAPI+ nuclei) was calculated in various regions of LV sections using fluorescent microscopy with a magnification of ×40. The density of cardiomyocyte nuclei was counted in at least 4 representative microscopic fields within each region of interest. The cardiomyocyte origin of the apoptotic cells was identified by immunohistochemical staining for α-actinin. The assay was standardized with the use of some sections treated with DNase I (1 U/mL for 30 minutes at 37°C) to induce the formation of DNA strand breaks (positive control of apoptosis).
**Statistical Analysis**

Continuous variables are presented as mean±SEM, and categorical data are summarized as frequencies or percentages. For categorical variables, differences between groups are evaluated with chi-squared test followed by Bonferroni correction. For continuous variables, normal distribution was evaluated with Kolmogorov-Smirnov test, and logarithmic or square-root transformations were performed on continuous variables of nonnormal distribution. Differences among groups were analyzed by 1-way analysis of variance followed by post hoc analysis (Bonferroni correction). GLM univariate analysis of variance (2-way analysis of variance) followed by Tukey HSD and Bonferroni were applied for multiple comparisons when there were more than 2 factors influencing a variable (effect of time point and treatment options on cardiac function). All analyses used 2-sided tests with an overall significance level of α=0.05 and were performed with SPSS 15.0 for Mac.

**Results**

**In Vitro Transduction: Localization and Confirmation**

Depending on its subcellular location, intracellular S100A1 modulates cardiac Ca\(^{2+}\) turnover via different Ca\(^{2+}\)-regulatory proteins.\(^{19}\) Our first goal was to demonstrate the location of endogenous S100A6 and that of our exogenous GFP-tagged S100A6 to ensure that binding to GFP (larger molecular mass of 27 kDa) did not change its localization and hence activity. Although transduced NRVMs showed predominantly cytoplasmic and perinuclear localization of exogenous GFP-tagged human S100A6 protein (Figure 1A), endogenous rat S100A6 showed predominantly cytoplasmic, but also nuclear localization (Figure 1B). We tested whether S100A6 could enter cells via endocytosis. After incubation of cells with exogenous S100A6-His fusion protein, staining for endogenous S100A6 and exogenous extracellular S100A6-His fusion protein showed the cytoplasmic uptake of exogenously added S100A6 in the presence of 2 mM L Ca\(^{2+}\) after 1 hour, which colocalized with endogenous S100A6 (both cytoplasmic and nuclear) (Figure 1C).

Real-time PCR data showed a significant rise in expression of human/rat S100A6 in S100A6-overexpressing cardiomyocytes and significantly decreased expression of endogenous rat S100A6 in S100A6 knockdown cardiomyocytes. Overexpression or knockdown of S100A6 had no influence on the expression of S100A1 or S100B (Figure 1D). We confirmed transduction of cardiomyocytes by Western blotting in S100A6-overexpressing and S100A6-knockdown cardiomyocytes, compared to untransfected controls (Figure 1E).

**Calcium Transients and CaN Activity In Vitro**

Calcium transients of S100A6-knockdown and S100A6-overexpressing neonatal cardiomyocytes were quantified using the fluorophore (Fura-2AM) 2 days after viral transduction. S100A6-overexpressing neonatal cardiomyocytes showed significantly increased calcium release amplitude. Moreover, S100A6-knockdown cardiomyocytes showed transients that had significantly lower amplitude, and the overall Ca\(^{2+}\) release rate was significantly decreased in the S100A6-knockdown compared to control cardiomyocytes (Figure 2A and 2B).

CaN, a calcium-dependent serine-threonine phosphatase, has antiapoptotic effects on cardiomyocytes in vitro\(^{20}\) and a cardioprotective role following myocardial I/R through the Nuclear factor of activated T-cells (NFAT) pathway.\(^{21,22}\) The phosphatase activity of CaN is mostly dependent on the level of free calcium.\(^{23}\) We measured the phosphatase activity of CaN in S100A6-overexpressing and S100A6-knockdown neonatal cardiomyocytes after H/R (24/6 hours) and normoxia compared to controls both as an indicator of free cytosolic calcium levels and as a key antiapoptotic molecule: CaN phosphatase activity was significantly higher in S100A6-overexpressing neonatal cardiomyocytes compared to null-transduced and nontransduced controls both after normoxia and H/R.(24/6 hours) (Figure 2C).

S100A6-overexpressing cardiomyocytes had significantly increased expression of CaN A after H/R compared to null-transduced and nontransduced controls, but S100A6 overexpression had no significant effect on CaN B, either during hypoxia or after H/R in vitro (Figure 2C).

**Effect of S100A6 on Apoptosis After H/R In Vitro**

We used H/R (1% O\(_2\), 20% CO\(_2\), and 79% N\(_2\) at 37°C for 24 hours, followed by 95% air and 5% CO\(_2\) at 37°C for 6 hours) as an in vitro surrogate for I/R. S100A6-overexpressing cardiomyocytes showed a significantly smaller number of apoptotic nuclei by TUNEL staining compared to null-transduced and nontransduced controls after H/R, whereas S100A6-knockdown cardiomyocytes showed a greater number of apoptotic nuclei both under normoxic conditions and after H/R (Figure 3A and 3B). TUNEL staining results were consistent with significantly lower caspase 3/7 activity in S100A6-overexpressing cardiomyocytes and higher caspase 3/7 activity in S100A6-knockdown cells compared to controls after H/R (Figure 3C).

**Effect of S100A6 Gene Delivery via UTMD on Cardiac I/R Injury**

We delivered human S100A6-N-emGFP plasmid DNA (500 µg of plasmid DNA [S100A6 or empty plasmid] coupled to 1×10\(^9\)
cationic lipid microbubbles) by UTMD 18 2 days prior to induction of I/R. UTMD of plasmid DNA results in peak transfection by day 2 to 3; thus, pretreatment allowed for maximal transgene expression at the time of cardiac I/R. The regional expression of S100A6 in the LV myocardium (anterior and posterior) on days 1, 7, and 28 post–cardiac I/R by
qRT-PCR (quantitative real-time PCR) is shown in Figure 4A through 4C. Our data show increased expression of human/rat S100A6 in the anterior LV of S100A6-treated rats at all time points post-I/R, with expression decreasing over time. S100A6 expression was lower in the posterior LV (Figure 4A through 4C).

Figure 2. Calcium transients and calcineurin (CaN) activity in vitro. A, Representative calcium transient imaging for nontransduced control, S100A6-knockdown (KD) and S100A6-overexpressing (OE) cardiomyocytes. B, The calcium release amplitude, the rate of calcium release and uptake in S100A6-overexpressing and S100A6-knockdown neonatal cardiomyocytes compared to nontransduced controls during spontaneous action potentials (mean±SEM, *P<0.05 vs nontransduced controls, N=7 for each). C, CaN phosphatase activity during normoxia and after H/R (24/6 hours) in S100A6-overexpressing and S100A6-knockdown neonatal cardiomyocytes compared to null-transduced and nontransduced controls and relative expression of CaN A and CaN B in S100A6-overexpressing, S100A6-knockdown, null-transduced, and nontransduced cardiomyocytes during normoxia and hypoxia/reoxygenation (mean±SEM, *P<0.05 vs null-transduced and nontransduced controls, N=7 for each).
The mortality rate after I/R induction surgery was significantly lower in the S100A6-pretreated animals compared to empty-plasmid–treated and nontreated controls (25% versus 55% and 42%, respectively, \( P < 0.05 \)) (Figure 4D), with all mortality occurring during ischemia or immediately on reperfusion. The LV ejection fraction and fractional area change by 2D echocardiography progressively improved in the S100A6-treated group compared to empty-plasmid–treated and nontreated controls up to day 28. The circumferential extent of the akinetic segment of the LV progressively decreased in S100A6-treated rats from day 3 to day 28 and became significantly smaller than empty-plasmid–treated and nontreated controls (Figure 4E through 4H).

**Effect of S100A6 Gene Delivery on Cardiac Hypertrophy and Fetal Gene Expression After Cardiac I/R Injury**

Body weight changes over 28 days post–I/R induction surgery were not significantly different between groups (data not shown). At day 28, S100A6-treated animals had a significantly lower heart weight to tibia length and heart
weight to body weight ratios compared to empty-plasmid–treated and nontreated controls (Figure 5A and 5B). In keeping with less cardiac hypertrophy in S100A6-treated hearts, cardiomyocyte size was significantly smaller in S100A6-treated rats in comparison to empty-plasmid– and nontreated controls at day 28 following I/R (Figure 5D). S100A6-treated hearts had significantly lower expression of βMHC and ANF, markers of myocardial hypertrophic phenotype, in the infarct and noninfarct regions of myocardium 28 days after I/R compared to empty-plasmid–treated and nontreated controls (Figure 5E and 5F).

**Effect of S100A6 Gene Delivery on Infarct Size and Myocardial Viability (Necrosis and Apoptosis)**

Despite pretreatment with S100A6 gene therapy 2 days before I/R, the risk area by Evans blue was similar across all treatment groups (Figure 6A and 6C). We used TTC staining to mark the infarcted area in LV myocardial sections 24 hours post-I/R, demonstrating that S100A6-treated rats had significantly smaller infarct size/nonviable myocardium at 24 hours post-I/R (control 24.8%, empty-treated 25.6%, and S100A6-treated 14.7%) (Figure 6B and 6E). Using Masson trichrome staining on LV sections at day 28 post-I/R, we...
Figure 5. Cardiac hypertrophy data post–myocardial ischemia-reperfusion. A, Ratio of heart weight to tibia length at day 28 post-I/R (mean±SEM, *P<0.05 vs nontreated and empty plasmid–treated controls, N=14-20 in each group). B, Ratio of heart weight to body weight at day 28 post-I/R (mean±SEM, *P<0.05 vs nontreated and empty plasmid–treated controls, N=14-20 in each group). C, Representative H&E-stained images of noninfarct sections of LV myocardium at day 28 post-I/R in (i) control, (ii) empty plasmid, and (iii) S100A6 plasmid delivered rats. D, Cardiomyocyte size at day 28 post-I/R (magnification ×100) (mean±SEM, *P<0.05 vs nontreated and empty plasmid–treated controls, N=50-60 cells in each group). E, Relative expression of βMHC in the infarct and noninfarct regions of myocardium 28 days post-I/R (mean±SEM, *P<0.05 vs nontreated and empty plasmid–treated controls, N=7 for all groups). F, Relative expression of ANF in the infarct and noninfarct regions of myocardium 28 days post-I/R (mean±SEM, *P<0.05 vs nontreated and empty plasmid–treated controls, N=7 for all groups). ANF, atrial natriuretic factor; βMHC, β-myosin heavy chain; H&E, hematoxylin and eosin; I/R, ischemia-reperfusion.
showed significantly smaller collagen-rich scar tissue in the LV of S100A6-treated rats compared to nontreated and empty-treated controls (control 24.0%, empty-treated 25.6%, and S100A6-treated 11.6%) (Figure 6C and 6F). These data show that S100A6 overexpression reduces acute infarct size and leads to a greater extent of viable myocardium post-I/R, smaller infarct scar size, thus allowing improved late recovery of LV systolic function.

We examined the antiapoptotic effects of S100A6 pretreatment in the myocardium at day 1 after I/R by TUNEL and caspase 3/7 activity assay. S100A6-pretreated animals showed significantly lower numbers of apoptotic cells by
TUNEL staining in the infarct and noninfarct regions of myocardium compared to empty-plasmid– and nontreated controls 28 days after I/R (Figure 6E and 6F). Caspase 3/7 activity at day 1 post-I/R was lower in the infarcted myocardium of S100A6-pretreated animals compared to empty-plasmid– and nontreated controls (Figure 6G). This finding is consistent with our in vitro data on S100A6-overexpressing neonatal cardiomyocytes post-H/R and suggests that the prosurvival effect of S100A6 during myocardial I/R injury is in part through inhibition of the intrinsic pathway of apoptosis. The magnitude of difference between S100A6-treated hearts and controls is greater for TUNEL (5- to 6-fold of apoptosis. The second EF-hand is a canonical 12-residue C-terminal EF-hand that ligates calcium in a similar manner to calmodulin and troponin C, resulting in a higher-calcium-affinity site with K_d ~1 to 50 μmol/L (ie, S100A6 K_d=3 μmol/L, S100A1 K_d≈27 μmol/L, and S100B K_d=50 μmol/L).25 The S100A6 target proteins identified thus far include mostly cytoskeletal proteins and components of heat shock protein complexes.28 It has been demonstrated that the calcium-dependent binding of S100A6 to its targets could interfere with their phosphorylation or could disrupt protein–protein interactions through competition.29 The role of extracellular S100A6 is not clear at present, but the obtained results suggest a possible involvement in cell survival through its binding to the transmembrane receptor for advanced glycation endproducts.30

Comparisons between S100A6 and S100A1, the most widely studied members of the S100 family of EF-hand calcium-binding proteins, show key similarities but also demonstrate important differences. Whereas S100A1 is highly expressed under basal conditions and is downregulated post-MI,31 S100A6 exhibits low basal cardiac expression with upregulation after acute MI.14 Forced expression of S100A6 in cardiomyocytes prevented apoptosis by interfering with p53 phosphorylation15 and inhibited the induction of the cardiac fetal gene promoters β-myosin heavy chain and skeletal α-actin.14 Cardiomyocyte-specific transgenic mice overexpressing S100A6 subjected to permanent LAD coronary ligation had less myocyte hypertrophy, interstitial fibrosis, and cardiomyocyte apoptosis, leading to greater preservation of LV systolic function compared to control animals.

The results of our study add to the existing data on S100A6, showing that S100A6 gene therapy delivered 2 days prior to LAD ligation and reperfusion helped ameliorate cardiac I/R injury. We performed LAD ligation and reperfusion blinded to which pretreatment animals had received, thereby allowing us to use mortality as 1 of the endpoints. Although S100A6 gene therapy provided a survival advantage after I/R, the challenge for translating this to clinical practice will be optimizing gene delivery for rapid transfection prior to or immediately after reperfusion. The exact mechanism behind this protective effect is unclear; however, we can speculate that the enhanced Ca^{2+} cycling would attenuate diastolic Ca^{2+} overload, thus suppressing arrhythmogenesis and leading to a reduction in reperfusion arrhythmias.32,33 All mortality occurred during occlusion or immediately on reperfusion, supporting an arrhythmic death.

We examined the role of intracellular S100A6 on Ca^{2+} homeostasis in neonatal ventricular cardiomyocytes in vitro. Whereas overexpression of S100A6 lead to increased amplitude of Ca^{2+} transients with enhanced release and uptake rates...
between the sarcoplasmic reticulum and the cytosol, knock-
down of S100A6 had the opposite results. Our findings are in
contrast to the results of Wang et al, who found that S100A6
did not significantly alter Ca²⁺ transients.³⁴ Our study used
rhythmically beating neonatal cardiac myocytes during sponta-
nous action potentials, whereas they investigated the effect
of S100A6 calcium handling in nonbeating adult cardiomy-
ocyes during stimulated action potentials. Adult cardiomy-
ocyes undergo phenotypic changes after isolation and culture
and lack spontaneous contraction. These distinctions over
neonatal cardiomyocytes and variations in calcium handling
between stimulated action potentials and spontaneous depo-
larization likely account for the differences between stud-
ies.³⁵,³⁶ We believe that the contractile profile during H/R of
cultured neonatal myocytes is more compatible with in situ
days during I/R. This effect on intracellular calcium transients
is similar to that of S100A1,¹⁹,³⁷ where intracellular S100A1
overexpression enhanced the Ca²⁺-transient amplitude in
cardiomyocytes via a stimulatory action on sarco/endoplasmic
reticulum Ca²⁺-ATPase and ryanodine receptor 2. Our data on
enhanced Ca²⁺ transients is the likely link to increased CaN
activity, which is driven by higher availability of free Ca²⁺.²³

Given the prosurvival and antiapoptotic role of CaN-NFAT
signaling in the heart,²⁰⁻²² the enhanced CaN activity likely
contributed to the existing antiapoptotic effects of S100A6
mediated through p53 phosphorylation.¹⁵ In contrast to
S100A6 effects, extracellular S100A1 inhibits apoptosis in
cardiomyocytes via activation of extracellular signal-regulated
kinase 1/2.³⁸ Although intracellular S100A1 also binds to
p53,³⁹ whether this plays a role in the antiapoptotic effect of
S100A1 has not been examined. To our knowledge, S100A1
effects on CaN have not been studied. Indeed, S100A1-
provoked Ca²⁺ cycling appears to bypass Ca²⁺-dependent
hypertrophic pathways such as those that involve activation of
protein kinase C and CaN.⁴⁰

Recently, the role of S100A6 in endothelial cell proliferation
has been elucidated.⁴¹ Lerchenmuller et al reported a previ-
ously unrecognized link between S100A6 and attenuation of
the antiproliferative signal transducers and activators of
transcription 1 (STAT1) in endothelial cells. In their study,
S100A6-depleted endothelial cells had activated STAT1,
whereas knockdown of STAT1 restored their proliferative
capacity via suppression of its downstream effector inter-
feron-inducible transmembrane protein 1.⁴¹ Given that
STAT1 activation plays a role in I/R-induced apoptosis,⁴² and STAT1
deficiency protects against myocardial infarction injury by
enhancing autophagy,⁴³ whether the positive effects of S100A6
on myocardial I/R are in part mediated by modulation of STAT1
signaling in cardiomyocytes is worthy of future study.

There are several important limitations to our study. The main
limitation is that S100A6 gene therapy was delivered 2 days
prior to coronary ligation. We did this to ensure maximal
transfection at the time of I/R, given that peak transfection of
3 days with UTMD³⁴ would prove less beneficial in the context of
the rapid response to injury. Our results still provide important
proof-of-concept data on the therapeutic benefit of S1006
therapy for prevention of cardiac I/R injury. We fully understand
the rapid response to injury. Our results still provide important
proof-of-concept data on the therapeutic benefit of S1006
treatment for prevention of cardiac I/R injury. We fully understand
that for clinical translation, more efficient, rapid transfection
techniques will be required for gene therapy at the time of
reperfusion, or protein-based therapies will need to be consid-
ered. Our recent work on UTMD of miRNA⁴⁵ showing transfection
as early as 3 hours post-UTMD suggests that miRNAs could be
an effective gene strategy to combat myocardial infarction and
I/R injury.⁴⁶ Finally, Ca²⁺ transients were measured during
the absence of stress. Further studies examining Ca²⁺ transients
under stimulation and after H/R are warranted.

In summary, the present study is the first to demonstrate the
therapeutic benefit of S100A6 gene therapy, with improved
survival, reduced infarct size, and greater myocardial
viability resulting in increased LV systolic function in the
setting of acute MI and I/R injury. These positive effects were
attributable not only to the known antiapoptotic and antihy-
pertrophic effects of S100A6 but also to enhanced Ca²⁺
cycling and CaN phosphatase activity. These results warrant
further studies exploring the therapeutic potential of S100A6
in cardiac diseases.

Sources of Funding
This work is supported by Operating Grants (MOP 62763 and
MOP 137109) from the Canadian Institutes of Health Research,
Ottawa, Ontario, Canada, and an Infrastructure Grant from the
Canadian Foundation for Innovation (26222), Ottawa, Ontario,
Canada. Dr Leong-Poi holds the Brazilian Ball Chair in
Cardiology from St. Michael’s Hospital, University of Toronto,
Canada. Dr Gramolini holds a Canada Research Chair in
Cardiovascular Proteomics and Molecular Therapeutics from
the University Health Network, University of Toronto, Canada.
Dr Connelly holds a New Investigator Award from the Canadian
Institutes of Health Research, Ottawa, Ontario, Canada.

Disclosures
None.

References
1. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y,
   Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR,
   Halvorsen S, Huber K, Grahek S, Fresco C, Bluhmki E, Regelin A, Vandenbergehe
   K, Bogaerts K, Van de Werf F. Fibrinolysis or primary PCI in ST-segment
   elevation myocardial infarction. N Engl J Med. 2013;368:1379–1387.
2. Bainey KR, Ferguson C, Ibrahim OJ, Tyrrell B, Welsh RC. Impact of reperfusion
   strategy on aborted myocardial infarction: insights from a large Canadian ST-
   Elevation Myocardial Infarction Clinical Registry. Can J Cardiol. 2014;30:1570–
   1575.
3. Sugiyama T, Hasegawa K, Kobayashi Y, Takahashi O, Fukui T, Tsugawa Y.
   Differential timing trends of outcomes and costs of care for acute myocardial
   infarction hospitalizations by ST elevation and type of intervention in the
1. Lambert LJ, Brophy JM, Racine N, Rinfret SL, L’Allier PL, Brown KA, Boothby LJ, Ross D, Segal E, Kou S, Maire S, Harvey R, Kezouh A, Nashmin J, Bogaty P. Outcomes of patients with ST-elevation myocardial infarction receiving and not receiving reperfusion therapy: the importance of examining all patients. *J Cardiol*. 2016;32:S25.e1113–S25.e1319.

2. Bousette N, Abbasi C, Chis R, Gramolini AO. Calnexin silencing in mouse. *J Cell Physiol*. 2014;229:374–383.

3. De Windt LJ, Lim HW, Taigen T, Wencker D, Condorelli G, Dorn GW II, Kitsis RN, Lee PJ, Rudenko D, Kuliszewski MA, Liao C, Kabir MG, Connelly KA, Leong-Poi H, Slomnicki LP, Filipek A, Krezel AM, Chazin W, Kuznicki J. Apoptosis-inducing factor (AIF): key mediator of S100A6 and S100P in serum levels with acute coronary syndromes in the adult heart. *Mol Cell Cardiol*. 2013;72:117–125.

4. Wang W, Asp ML, Guerrero-Serna G, Metzger JM. Differential effects of S100 proteins on apoptosis and mitochondrial function in cardiac myocytes during ischemia and reperfusion. *Cell Calcium*. 2012;51:445–451.

5. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. *N Engl J Med*. 2007;357:1121–1135.

6. Etienne-Cummings R, Chui I, Tschlier W, et al. S100P: a potential marker of cardiac ischemia-reperfusion injury. *J Clin Invest*. 2013;123:92–100.

7. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. *J Clin Invest*. 2013;123:92–100.

8. Wang S, Chen J, Valderrabano M. Nutrient restriction preserves calcium cycling and mitochondrial function in cardiac myocytes during ischemia and reperfusion. *Cell Calcium*. 2012;51:445–451.

9. Tschlier W, Yellon DM, Osseiran M, Gavras H. Survivin gene therapy attenuates left ventricular systolic dysfunction in rat models with ischemia-reperfusion injury. *Atherosclerosis*. 2011;217:536–542.

10. Tohse T, Nagashima M, Yamada Y, Tsutsuura M, Kobayashi T, Namiki A. Apoptosis and cell death in the adult heart. *Cardiovasc Res*. 2008;79:262–267.

11. Kloner RA. Current state of clinical translation of cardioprotective agents for acute myocardial infarction. *Circ Res*. 2013;113:451–463.

12. Nowotny M, Bhattacharya S, Filipek A, Krezel AM, Chazin W, Kuznicki J. Characterization of the interaction of calcyclin (S100A6) and calcyclin-binding protein. *J Biol Chem*. 2000;275:31178–31182.

13. Cai XY, Lu L, Wang YN, Jin C, Zhang RY, Zhang Q, Chen QJ, Shen WF. Association of increased S100B, S100A6 and S100P in serum levels with acute coronary syndrome and also with the severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury. *Atherosclerosis*. 2011;217:536–542.

14. Tschlier W, Marks A, Haddad A, O’Hanlon D, Jolly S, Parker TG. S100A6 is a negative regulator of the induction of cardiac genes by trophic stimuli in cultured rat myocytes. *Exp Cell Res*. 2005;303:471–481.

15. Tschlier W, Ihsar S, Parker TG. Expression of S100A6 in cardiac myocytes limits apoptosis induced by tumor necrosis factor-α. *J Biol Chem*. 2008;283:30174–30183.

16. Tschlier W, Ihsar S, Desjardins JF, Leong-Poi H, Parker TG. Cardiac mitochondrial overexpression of S100A6 attenuates myocyte hypertrophy and apoptosis following myocardial infarction. *Curr Pharm Des*. 2014;20:1941–1949.

17. Boussat N, Abbas C, Chis R, Gramolini AO. Calcinexin silencing in mouse neonatal cardiomyocytes induces Ca2+-dependent ER stress, ER apoptosis, and apoptosis. *J Cell Physiol*. 2014;229:374–383.

18. Lee PJ, Rudenko D, Kuliszewski MA, Liao C, Kabir MG, Connolly KA, Leong-Poi H. Survivin gene therapy attenuates left ventricular systolic dysfunction in doxorubicin cardiomyopathy by reducing apoptosis and fibrosis. *Cardiovasc Res*. 2014;101:423–433.

19. Most P, Boerries M, Eicher C, Schweda C, Volkers M, Wedel T, Sollner S, Katus HA, Remppis A, Abei U, Koch WJ, Schonenberger CA. Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes. *J Cell Sci*. 2005;118:421–431.

20. De Windt LJ, Lim HW, Taigen T, Wencker D, Condorelli G, Dorn GW II, Kittis RN, Molkentin JD. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: an apoptosis-independent model of dilated heart failure. *Circ Res*. 2000;86:255–263.

21. Obasanjo-Blackshire K, Mesquta R, Jabl RI, Molkentin JD, Hart SL, Marber MS, Xia Y, Heads RJ. Calcineurin regulates NFAT-dependent INOS expression and protection of cardiomyocytes: co-operation with Src tyrosine kinase. *Cardiovasc Res*. 2000;47:672–683.

22. Bueno OF, Lips DJ, Kaiser RA, Wilkins BJ, Dai YS, Glasscock BJ, Klevisky R, Hewett TE, Kimball TR, Aronow D, Doevendans PA, Molkentin JD, Molkentin AJ. Gene targeting predisposes the myocardium to acute ischemia-induced apoptosis and dysfunction. *Circ Res*. 2004;94:91–99.

23. Perrino BA, Ng LY, Soderling TR, Calcium regulation of calcineurin phosphatase activity by its B subunit and calmodulin. Role of the autoinhibitory domain. *J Biol Chem*. 1999;274:340–346.